A thrombin-PAR1/2 feedback loop amplifies thromboinflammatory endothelial responses to the viral RNA analogue poly(I:C)

Saravanan Subramaniam,1 Yamini Ogoti,1 Irene Hernandez,1 Mark Zogg,1 Fady Botros,1 Robert Burns,1 Jacob T. DeRousse,2 Chris Dockendorff,2,3 Nigel Mackman,4 Silvio Antoniak,5 Craig Fletcher,5 and Hartmut Weiler1

1Blood Research Institute, Blood Center of Wisconsin, Versiti, Milwaukee, WI; 2Department of Chemistry, Marquette University, Milwaukee, WI; 3Function Therapeutics LLC, Milwaukee, WI; and 4Department of Medicine, Division of Hematology and Oncology, and 5Department of Pathology and Laboratory Medicine, UNC Blood Research Center, University of North Carolina, Chapel Hill, NC

Key Points

- Thrombin and the viral RNA analogue poly(I:C) cooperatively amplify endothelial prothrombotic and proinflammatory function.
- Inhibition of PAR2 reduces the expression of tissue factor and leukocyte recruitment by endothelial cells.

Activation of blood coagulation and endothelial inflammation are hallmarks of respiratory infections with RNA viruses that contribute significantly to the morbidity and mortality of patients with severe disease. We investigated how signaling by coagulation proteases affects the quality and extent of the response to the TLR3-ligand poly(I:C) in human endothelial cells. Genome-wide RNA profiling documented additive and synergistic effects of thrombin and poly(I:C) on the expression level of many genes. The most significantly active genes exhibiting synergistic induction by costimulation with thrombin and poly(I:C) included the key mediators of 2 critical biological mechanisms known to promote endothelial thromboinflammatory functions: the initiation of blood coagulation by tissue factor and the control of leukocyte trafficking by the endothelial-leukocyte adhesion receptors E-selectin (gene symbol, SELE) and VCAM1, and the cytokines and chemokines CXCL8, IL-6, CXCL2, and CCL20. Mechanistic studies have indicated that synergistic costimulation with thrombin and poly(I:C) requires proteolytic activation of protease-activated receptor 1 (PAR1) by thrombin and transactivation of PAR2 by the PAR1-tethered ligand. Accordingly, a small-molecule PAR2 inhibitor suppressed poly(I:C)/thrombin-induced leukocyte-endothelial adhesion, cytokine production, and endothelial tissue factor expression. In summary, this study describes a positive feedback mechanism by which thrombin sustains and amplifies the prothrombotic and proinflammatory function of endothelial cells exposed to the viral RNA analogue, poly(I:C) via activation of PAR1/2.

Introduction

Activation of blood coagulation is invariably linked to the innate immune response to infection by viral and bacterial pathogens, secondary to augmented expression of the initiator of the extrinsic pathway of blood coagulation, tissue factor (TF; gene symbol, F3) on innate immune cells and vascular endothelial cells (ECs).1-3 Aberrant coagulation activation and thrombosis have been recognized as a contributing factor in the pathology of respiratory tract infections with influenza A viruses, Middle East respiratory syndrome, and severe acute respiratory syndrome coronavirus (SARS-CoV1 and -2).4-6 The thrombotic coagulopathy affecting the pulmonary circulation and secondary organs such as the liver and kidneys of patients with COVID-19,7-14 together with early clinical observations indicating a potential benefit of anticoagulant...
interventions,\textsuperscript{15–17} suggest that dysregulated coagulation contributes significantly to the morbidity and mortality of patients with severe disease.

The extent of coagulopathy triggered by single-stranded RNA viruses has led to suggestions that the acute thrombotic pathology associated with respiratory tract infection may in part be caused by excessive EC injury and inflammatory activation.\textsuperscript{18–21} This state of endothelial activation comprises wide-ranging adaptations that support a localized immune response by facilitating leukocyte trafficking across the blood-tissue barrier, controlling blood supply to sites of infections, regulating blood pressure, and promoting the localized activation of platelets and the blood coagulation mechanism. Dysregulation of these responses caused by excessive, sustained elaboration of proinflammatory mediators and cytokines, as it occurs in systemic inflammatory response syndrome and severe sepsis, has been linked to life-threatening failure to sustain adequate blood pressure, microvascular thrombosis, and, in the most severe cases, to disseminated intravascular coagulation and multiorgan failure.

The TF/FVIIa complex–initiated activation of the coagulation proteases factor VII and X and the ensuing downstream generation of thrombin not only trigger the procoagulant state associated with infection, but in addition may modulate cellular functions via G-protein–coupled protease-activated receptors (PARs) 1, 2, and 4 (reviewed in Posma et al\textsuperscript{22} and Samad and Ruf\textsuperscript{23}). Experimental evidence indicates that thrombin signaling via PARs alters the function of human ECs in a manner similar to inflammatory cytokines, including increased leukocyte trafficking, permeability, vasomotor tone, angiogenesis, and TF expression.\textsuperscript{24–27}

The role of direct endothelial infection by viral pathogens remains to be fully explored. For example, ECs express the primary receptor for SARS-Cov1/2 and angiotensin-converting enzyme 2, and elevated endothelial angiotensin-converting enzyme 2 is associated with the cardiovascular risk factors predictive of increased morbidity.\textsuperscript{28,29} SARS-CoV-2 RNA has been detected in the peripheral blood of some patients with severe disease\textsuperscript{30} and the virus infects ECs in vitro\textsuperscript{31} and in vivo.\textsuperscript{18,32} A significant role for ECs as the source of procoagulant activity and cytokine production induced by viral infection is further suggested by the observation that the viral RNA analogue polyinosinic:polycytidylic acid (poly[\textit{I}:\textit{C}]) induces both cytokine production and TF-procoagulant activity via Toll-like receptor 3 (TLR3) in human umbilical vein ECs (HUVECs). In contrast, poly[\textit{I}:\textit{C}] induces the release of cytokines, but not TF expression in human peripheral blood-derived monocytes.\textsuperscript{33}

In the current work, we investigated how signaling by TF and activated coagulation proteases affects the EC response to the viral RNA analogue and TLR3-ligand poly(I:C).

\section*{Materials and methods}

\subsection*{Cell culture}

EA.hy926 cells (CRL-2922; ATCC) were cultured in Dulbecco’s modified Eagle’s medium with 20 mM HEPES, 4 mM glutamine, 1 mM sodium pyruvate, 0.75 g/L sodium bicarbonate, 100 U/mL penicillin, 100 \mu g/mL streptomycin, and 10% fetal bovine serum. Pooled HUVECs (cat. no. C2517A; Lonza, Walkersville, MD) were cultured in endothelial basal medium (cat. no. CC-3162; Lonza), containing 1 \mu g/mL hydrocortisone, 10 ng/mL epidermal growth factor, 10 ng/mL basic fibroblast growth factor, and 5% (v/v) fetal calf serum. THP-1 cells (TIB-202; ATCC) were cultured in RPMI 1640 (Life Technologies, Grand Island, NY) supplemented with 10% fetal bovine serum, 10 mM HEPES, 0.1 mM minimum essential medium nonessential amino acids, 1 mM sodium pyruvate, and 100 nM penicillin/streptomycin (Life Technologies), in 5% CO\textsubscript{2} at 37°C.

\subsection*{TF activity}

Total and cell surface TF activity were measured by 1-stage clotting assays and 2-stage FXa generation assays, respectively, as described,\textsuperscript{33} with the anti-TF antibody HTF-1\textsuperscript{34} (10 \mu g/mL). Clotting times were converted into procoagulant activity from a standard curve generated with human TF (Innovin; Dade Behring, Germany). The PAR1 and PAR2 cleavage-blocking antibodies ATAP2 (10 \mu g/mL), WEDE15 (10 \mu g/mL), SAM-11 (10 \mu g/mL), vorapaxar (1 \mu g/mL), and GBB83 (25 \mu M) were added 1 hour before poly(I:C) and/or thrombin.

\subsection*{Quantitative reverse transcription–real-time PCR}

Total RNA was extracted with TRizol (Life Technologies, Carlsbad, CA) and transcribed into cDNA using the QuantiTect Reverse transcription kit (Qiagen), and transcript levels were quantified by TaqMan PCR assays with commercially available primer sets (Applied Biosystems), by the \textit{ΔΔCt} method, with glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as a normalizing control.\textsuperscript{35}

\subsection*{RNA sequencing}

cDNA libraries were prepared from poly(A)-selected RNA (NEBNext Poly[A] messenger RNA [mRNA] magnetic isolation kit) with the NEBNext Ultra RNA Library Prep Kit (cat. no. E7530; NEB) and sequenced with the Illumina NextSeq 500 system (75 cycles). Sequence data were demultiplexed by using bcl2fastq v2.20.0.422 and aligned and quantitated with ARMOR pipeline v1.2.2 and Ensemble Human genome GRCh38 release 93 as the reference. Expression quantities were imported into R v3.5.3 and summarized at the gene level by using tximport v1.10.0. All samples were normalized, and gene expression was compared between conditions with Wald tests in DESeq2 v1.22.1. \textit{P}-values were corrected for multiple tests by the Benjamini-Hochberg method. Log-fold changes were shrunken by using the normal method in DESeq2. Genes with an adjusted \textit{P} < .05 (\textit{P}_{adj}) were considered to be significantly differentially expressed. Differentially expressed genes were annotated using the Gene Ontology database (https://biit.cs.ut.ee/gprofiler) to examine the biological functions and pathways of the genes.

\subsection*{Western blot analysis}

ECs were lysed in RIPA buffer (Invitrogen, Rockford, IL), subjected to electrophoresis on 10% sodium dodecyl sulfate-polyacrylamide gels (Mini-PROTEAN TGX; Bio-Rad) under reducing conditions, and transferred to 0.2-\mu m PVDF membranes on a Trans-blot TURBO transfer system (Bio-Rad). Membranes were probed with mouse anti-human TF (clone, VIC7; Sekisui Diagnostics, Darmstadt, Germany) and mouse anti-human β-tubulin (clone, BT7R; Invitrogen) primary antibodies, followed by horseradish peroxidase (HRP)-conjugated secondary antibodies, and imaged on an American Imager 680 (General Electric). Band density was quantified with ImageJ software (National Institutes of Health, http://rsb.info.nih.gov/ij/).
**Up and down regulated genes**

Poly(I:C) (66/14) Thrombin (143/69)

18 /12 (A)  D0/0 (D)  17/0 (F)  31/2 (E)  127/120 (C)  64/32 (G)

Poly(I:C) + Thrombin (239/154)

---

**Immunofluorescence microscopy**

Cells were cultured on coverslips, fixed for 1 hour at 4°C in phosphate-buffered saline (PBS)-4% paraformaldehyde, permeabilized with 0.1% Triton X-100 in PBS for 5 minutes when indicated, blocked with 2% bovine serum albumin-PBS for 1 hour, incubated overnight at 4°C with mouse anti-human TF mAb (clone VIC7; 1:1000) or isotype-control followed by FITC-conjugated anti-mouse IgG for 60 minutes, mounted in 4',6-diamidino-2-phenylindole medium (ProLong Gold antifade reagent; Invitrogen), and imaged on a Nikon Eclipse Ti2 inverted microscope at ×60 original magnification. Images of nonpermeabilized cells were acquired on a FV1000-MPE Laser Scanning Confocal and Multiphoton Microscope (Olympus) at ×100 original magnification.

![Figure 1. Transcriptional profiling of HUVEC responses to poly(I:C) and thrombin.](http://ashpublications.org/bloodadvances/article-pdf/5/13/2760/1813608/advancesadv2021004360.pdf)
Generation of Thbd-deficient EA.hy926 cells

Guide RNA sequences targeting the 5'- and 3'-UTRs of the thrombomodulin (Thbd) gene (5'-UTR target: 5'-GCAGGCGCCGGG-GAAAGCGC-3'; 3'-untranslated region (UTR) target: 5'-TGAATTTGGATATCTCGCAG-3') were cloned into the Cas9 expression plasmid pX459.V2 (cat. no. 62988; Addgene), and the recombinant plasmids were cotransfected into EA.hy926 cells by nucleofection (Cell Line Optimization 4D-Nucleofector X Kit; Lonza). After expansion, Thbd-deficient cells were enriched by fluorescence-activated cell sorting with phycoerythrin (PE)-conjugated anti-Thbd antibodies (CD141/BDCA-3-PE, cat. no. 130-090-514; Miltenyi Biotec), as a pooled population or by sorting single Thbd2 cells into 96 wells, followed by expansion and validation of Thbd negativity by flow cytometry and PCR amplification/sequencing of the modified Thbd locus ("single-cell clone").

Flow cytometry

Single-cell suspensions prepared with cell dissociation buffer (Gibco) were incubated with PE-conjugated mouse anti-human E-selectin, APC-conjugated mouse anti-human VCAM1, or nonimmune isotype controls (cat. no. 322605; CD62E-PE; cat. no. 305809; CD106-APC, BioLegend; mouse IgG2a and IgG1; cat. no MA5-14453 and 6-4724-82; eBioscience) and analyzed on a BD Accuri C6 flow cytometer.

EC-leukocyte adhesion assay

HUVECs cultured in 12-well dishes were treated for 6 hours with poly(I:C) and/or thrombin and washed with PBS, and THP-1 cells labeled with rhodamine B isothiocyanate-dextran (Signa Aldrich) were added. After 1 hour, unbound cells were removed by 3 PBS washes, and bound cells were counted under a fluorescence microscope (Olympus BX-51). Vorapaxar (1 μg/mL) or GBB3 (25 μM) was added 1 hour before the THP-1 cells, and VCAM1 and E-selectin–blocking antibodies (10 μg/mL) were added 30 minutes before the THP-1 cells.

Statistical analysis

Statistical analysis was performed with Prism 8 software (GraphPad) by 1-way analysis of variance (ANOVA) for multiple groups and the Bonferroni multiple-comparisons test or Student t test for 2 groups.

Results

Genome-wide transcriptome effects of costimulation with thrombin and poly(I:C)

Triplicate cultures of HUVECs were treated for 3 hours with poly(I:C) and/or thrombin and subjected to transcriptional profiling.

Table 1 Transcripts upregulated or downregulated ≥2.5-fold by costimulation with poly(I:C) and thrombin, relative to poly(I:C) alone

| Gene  | Poly(I:C) vs control | Thrombin vs control | Poly(I:C) vs thrombin | Poly(I:C) vs poly(I:C) | Poly(I:C) vs thrombin |
|-------|---------------------|---------------------|----------------------|-----------------------|----------------------|
| SELE  | 13.12               | 3.85                | 4.14                 | 3.41                  | 3.17                 |
| VCA1  | 9.72                | 2.79                | 3.09                 | 3.48                  | 3.15                 |
| CXCL8 | 6.66                | 1.88                | 3.4                  | 3.54                  | 1.96                 |
| F3    | 6.47                | 1.33                | 2.36                 | 6.59                  | 2.74                 |
| CXCL2 | 5.46                | 1.86                | 1.91                 | 2.94                  | 2.86                 |
| NR4A1 | 4.32                | 1.52                | 4.42                 | 6.53                  | 0.98                 |
| CXCL3 | 4.22                | 1.22                | 2.24                 | 3.46                  | 1.88                 |
| IL6   | 3.14                | 1.12                | 1.8                  | 2.8                   | 1.74                 |
| MUC16 | 3.03                | 1.2                 | 1.28                 | 3.64                  | 3.88                 |
| C11orf96 | 3.01              | 1.18                | 1.62                 | 3.54                  | 1.86                 |
| CCL20 | 3.01                | 1.01                | 2.02                 | 3                     | 1.49                 |
| PTGS2 | 2.85                | 1.02                | 2.43                 | 2.9                   | 1.17                 |
| HLX   | 2.63                | 1.06                | 3.23                 | 3                     | 0.88                 |
| NR4A2 | 2.78                | 1.45                | 2.97                 | 4.02                  | 1.28                 |
| FST   | 2.68                | 1.16                | 2.92                 | 3.1                   | 0.92                 |
| PMCH  | 2.64                | 1.54                | 3                    | 4.06                  | 0.88                 |
| RCAN1 | 2.57                | 1.11                | 2.08                 | 2.85                  | 1.24                 |
| ADGB  | 2.46                | 1.22                | 1.08                 | 3.01                  | 2.66                 |
| BCL2A1| 2.42                | 1.39                | 1.59                 | 3.37                  | 1.52                 |
| UBE3D | 2.38                | 1.12                | 1.25                 | 2.68                  | 2.98                 |
| DKK2  | 2.31                | 1.56                | 2.06                 | 3.61                  | 1.12                 |
| CD11E | 2.1                 | 1.22                | 1.22                 | 2.57                  | 2.56                 |
| LBH   | 1.8                 | 1.43                | 2.59                 | 2.56                  | 0.69                 |
| IL11  | 1.74                | 1.47                | 2.28                 | 2.56                  | 0.76                 |
| CYSLTR2| −1.96               | 1.31               | −1.39                | −2.58                 | 1.41                 |
| TRIL  | −2.94               | −1.14               | −1.96                | −2.58                 | 1.50                 |

All genes were differentially expressed with an $P_{adj} < .05$, measured with DESeq2 v1.22.1.
transcripts, and genes associated with controlling leukocyte migration and adhesion, interferon-responsive included increased transcript levels for receptors and chemokines (Figure 1; supplemental File 1). In line with independent studies, similar to that described earlier,33,37-39 poly(I:C) (12.5 μg/mL) and PAR-specific agonist peptides (150 μM; PAR-1, SFLLRN-NH2 and TFRGAP-NH2) increased transcript levels for PAR-1 and PAR-2 (48-fold vs unstimulated cells; \( P_{\text{adj}} < .05 \)) that partially overlapped with the response to poly(I:C) (4.0-fold vs unstimulated cells; \( P_{\text{adj}} < .05 \)).

Likewise, a large number of genes regulated by costimulation were significantly upregulated and downregulated only in costimulated cells (Figure 1; Venn section C). This pool included many genes with validated functions in ECs, such as ACHE, CEBPD, GDF6, C2CD4B, ADORA2B, and NEDD4,42-47 or with candidate functions established in non-EC types, such as CARDB8, GBP2, REL, UGT8, and POU2AF1. The results of an analysis of expression data for genes in Venn section F with Ingenuity Pathway Analysis tools and gene annotations of biological functions and pathways curated in the NCBI Gene Ontology database was consistent with a general transcriptional activation and a predominant effect on inflammatory endothelial activation (Figure 1; supplemental File 1). In line with independent studies,48,49 thrombin likewise induced a proinflammatory gene signature (143 up and 69 down >1.5-fold vs unstimulated cells; \( P_{\text{adj}} < .05 \)) that partially overlapped with the response to poly(I:C) (Figure 1; Venn section F).

Genes within this overlapping subset regulate critical aspects of leukocyte trafficking (such as VCAM1, E-selectin [gene symbol: SELE], ICAM1, and CXCL1 and 8) and endothelial function in conditions of inflammatory stress (such as JUNB, NFKB2, RELB, CD69, and SOD2; Figure 1; supplemental File 1). Approximately half of the gene responses in costimulated cells were dominated by either thrombin or poly(I:C) (Figure 1; Venn sections E and G). For example, the expression of core interferon-responsive genes (such as APOL2; RIPK2; OASL; IFI44; IFIT family members 1, 2, and 3; and IRF1) was strongly induced by poly(I:C), but not by thrombin, and was sustained in costimulated cells at approximately the same level as in cells treated with poly(I:C) alone. Likewise, a large number of genes regulated by costimulation were selectively sensitive to thrombin, with little or no contribution of poly(I:C).

Notably, a large number of genes were significantly upregulated and downregulated only in costimulated cells (Figure 1; Venn section C). This pool included many genes with validated functions in ECs, such as ACHE, CEBPD, GDF6, C2CD4B, ADORA2B, and NEDD4,42-47 or with candidate functions established in non-EC types, such as CARDB8, GBP2, REL, UGT8, and POU2AF1 (for a full list, see supplemental File 1). The results of an analysis of expression data for genes in Venn section F with Ingenuity Pathway Analysis tools and gene annotations of biological functions and pathways curated in the NCBI Gene Ontology database was consistent with a general transcriptional activation and a predominant effect on inflammatory responses (supplemental File 2; pathway analysis). The bias toward inflammatory endothelial activation was more pronounced in upregulated genes, whereas database-curated candidate endothelial functions associated with downregulated genes included angiogenesis, vasculogenesis, and vascular integrity.

Importantly, genes affected most by costimulation (fold up/down change in costimulated cells vs poly(I:C) alone, <2.5; Table 1) included TF (F3), cyclooxygenase 2 (PTGS2, alias COX2), E-selectin, VCAM1, interleukin-8 (CXCL8), interleukin-6, chemokine (C-X-C motif) ligands-2/3 (CXCL2/3), C-C motif chemokine ligand-20 (CCL20), and the transcription factors NURR4A1 and 2 (alias NURR77/TR3 and NURR1), which are known to regulate critical endothelial functions in thrombus resolution,48 interactions with
leukocytes, proliferation, microvascular barrier maintenance, and the inflammatory response to TNFα. Overall, these analyses documented that costimulation with thrombin quantitatively and qualitatively altered the mRNA profile of ECs exposed to poly(I:C) and that biological mechanisms regulated most significantly at the mRNA level by costimulation included the initiation of blood coagulation and the control of leukocyte trafficking.

**PAR1 or PAR2 activation amplifies poly(I:C)-induced TF and CXCL8 mRNA**

EA.hy926 cells and HUVECs were treated with a combination of poly(I:C) and agonists for PAR1 (TFLLRN-NH₂), PAR1/2 (SFLLRN-NH₂), PAR2 (SLIKGV-NH₂), PAR3 (TFRGAP-NH₂), or PAR4 (GYPGV-NH₂). In both cell types, poly(I:C) increased TF and CXCL8 mRNA abundance. Agonist peptides for PAR1 and PAR2, but not for PAR3 or PAR4, elicited a 4- to 10-fold increase in TF and CXCL8 mRNA in the absence of poly(I:C) and significantly augmented the poly(I:C) response (Figure 2).
Figure 4. Thrombin augments poly(I:C)-induced TF and CXCL8 mRNA induction by activating PAR1/2 heterodimers. (A) Cell surface Thbd expression level in pool-sorted and single-cell clone Thbd-deficient EA.hy926 cells by flow cytometry. Shaded, nonimmune isotype control; black, parent (Thbd-expressing) cells; and red, Thbd-deficient cells. The numbers in the plots indicate the percentage of estimated maximum contamination, with cells expressing Thbd from 1 residual allele. (B) TM-deficient, pool-sorted cells and single-cell clones were stimulated with poly(I:C) (12.5 μg/mL) and thrombin (5 nM) for 3 hours. TF and CXCL8 mRNA abundance relative to GAPDH was measured by RT-PCR (n = 3-6; in duplicate). (C) EA.hy926 cells were pretreated with PAR1 (WEDE15, 10 μg/mL; ATAP2 10 μg/mL) and/or PAR2 (SAM-11, 10 μg/mL)
Figure 4. (continued) cleavage-blocking antibodies, followed by treatment with poly(I:C) (12.5 μg/mL) and/or thrombin (5 nM) for 3 hours. TF and CXCL8 mRNA abundance relative to GAPDH was measured by RT-PCR (n = 3-12; in duplicate). (D) EA.hy926 cells were pretreated with PAR-specific inhibitors (PAR1, vorapaxar, 1 μM; PAR2, GB83, 25 μM) followed by stimulation with poly(I:C) (12.5 μg/mL) and PAR1/2 agonist peptides. TF and CXCL8 mRNA abundance relative to GAPDH mRNA was measured by RT-PCR (n = 3-9; in duplicate). Data are expressed as the mean ± standard deviation. The statistical significance of differences between groups was analyzed by ANOVA followed by the multiple-comparison test. *P < .05; **P < .01; ***P < .001; ****P < .0001. ns, nonsignificant.

Figure 5. Thrombin-PAR1/2 signaling amplifies cell surface-associated TF procoagulant activity in poly(I:C)-treated cells. (A) EA.hy926 cells were stimulated with poly(I:C) (12.5 μg/mL) and PAR1-selective (SFLRN) or PAR2-selective agonist peptides (150 μM) for 4 hours, and TF and THBD antigen were detected by immunofluorescence in permeabilized cells. Original magnification, ×40; bar represents 10 μm; nuclear counterstain with 4',6-diamidino-2-phenylindole (n = 3). (B) EA.hy926 cells were stimulated with poly(I:C) (12.5 μg/mL) and PAR1 and PAR2 activation peptides for 6 hours in triplicate, and the protein levels of TF and β-tubulin were determined by western blot analysis with the respective antibodies. Data shown in the bar graph represent the mean ± standard deviation of the ratio of TF to β-tubulin, determined by quantitative densitometry of western blots (n = 3). (C) Cell lysates were prepared from EA.hy926 cells stimulated with poly(I:C) (12.5 μg/mL) and PAR1- and PAR2-activation peptides (150 μM) for 6 hours. TF procoagulant activity (PCA) was measured in the presence or absence of anti-TF antibody (HTF-1; 10 μg/mL) or IgG control (IgG2a; 10 μg/mL) by a 1-stage clotting assay and converted into picograms TF per milligrams protein from a standard curve generated with recombinant TF (Innovin; n = 3). (D) Cell-surface TF activity on intact cells was determined by an FXa generation assay (n = 5-6). (E) EA.hy926 cells were stimulated for 6 hours with poly(I:C) (12.5 μg/mL) and PAR1- and PAR2-activation peptides (150 μM) for 6 hours. TF procoagulant activity was measured by a 1-stage clotting assay and converted into PCA via a standard curve generated with recombinant TF (Innovin; n = 3). (F) Immunofluorescence detection of cell-surface TF and Thbd antigen on EA.hy926 cells stimulated for 4 hours with poly(I:C) (12.5 μg/mL) and/or thrombin (original magnification, ×100; bar represents 10 μm; n = 3). (G) EA.hy926 cells were pretreated for 45 minutes with inhibitors of PAR1 (vorapaxar, 1 μM) and/or PAR2 (GB83, 25 μM) followed by stimulation with poly(I:C) (12.5 μg/mL) and PAR1- and PAR2-activation peptides (150 μM) for 6 hours. Cell-surface TF activity was determined by FXa generation (n = 8). (H) EA.hy926 cells were pretreated for 45 minutes with PAR-specific inhibitors (vorapaxar, 1 μM; GB83, 25 μM) followed by stimulation with poly(I:C) (12.5 μg/mL) and/or thrombin for 6 hours. Abundance of TF and β-tubulin in whole-cell lysates were determined by western blot analysis (n = 3). (I) EA.hy926 cells were pretreated (45 minutes) with cleavage-blocking antibodies for PAR1 (WEDE15, 10 μg/mL; ATAP2, 10 μg/mL) and/or PAR2 (SAM-11, 10 μg/mL), or isotype-matched nonimmune IgG controls followed by
with both agonists (Figure 3E). Correspondingly, HUVECs and EA.hy926 cells exhibited increased sensitivity to stimulation with thrombin or poly(I:C), respectively (Figure 3F).

**Thrombin amplifies the poly(I:C) response via Par1-Par2 heterodimers**

Thrombin activates Par1 via cleavage at Arg41, which may lead to nonproteolytic transactivation of Par2.53 Alternatively, thrombin bound to Thbd may directly cleave and activate Par2 at Arg36.54 To address the latter mechanism, we generated Thbd-deficient EA.hy926 cells via CRISPR/Cas9-mediated gene editing (Figure 4A). Thrombin augmented the abundance of TF- and CXCL8-mRNA in poly(I:C)-treated, Thbd-deficient cells to an extent similar to that in Thbd-expressing wild-type cells (Figure 4B), arguing against a significant role of direct Par2 cleavage by the thrombin-Thbd complex.

Antibodies ATAP2 and WEDE15, which block Arg41 cleavage and thrombin binding to PAR1,55,56 prevented thrombin-mediated augmentation of poly(I:C)-induced TF mRNA abundance. In contrast, the PAR2 cleavage-blocking antibody SAM-11 had no effect (Figure 4C). The PAR2 antagonist GB83 abrogated the increase in TF- and CXCL8 mRNA (Figure 4D), but did not inhibit the mobilization of

---

**Figure 6. Leukocyte-endothelial interactions.** (A) HUVECs were treated with poly(I:C) (12.5 μg/mL) and thrombin (5 nM) for 3 hours, and the abundance of E-selectin and VCAM-1 mRNA relative to GAPDH was measured by quantitative RT-PCR. (B) Representative scatterplots depicting cell surface expression of VCAM-1 and E-selection determined by flow cytometry in HUVECs treated for 4 hours with poly(I:C) and/or thrombin. (C-D) Representative micrographs of static adhesion assay of rhodamine B-labeled THP-1 cells to HUVECs treated with poly(I:C) and/or thrombin, vorapaxar, GB83, or anti-E-selectin- and anti-VCAM1 blocking antibodies (10 μg/mL) and respective nonimmune IgG controls (10 μg/mL). Original magnification, ×20. Brightness adjusted to 75% with Powerpoint picture correction. Bars represent 200 μm. (D) The mean ± standard deviation of adherent THP-1 cells per visual field from 2 independent experiments (n = 9 for control, thrombin, poly(I:C); n = 6 for anti-VCAM-1/E-selectin). *P < .05; **P < .01; ***P < .001; ****P < .0001 by ANOVA, followed by multiple comparison test.
intracellular Ca^{2+} by thrombin or the PAR1-selective agonist peptide TFLLRN-NH_{2}, indicating that the inhibitory effect of GB83 is unlikely to involve off-target effects on PAR1 (supplemental Figure 1). In contrast, the PAR1 antagonist vorapaxar had no effect on the response to the PAR2 agonist peptide (Figure 4D), which suggests that thrombin augmented TF and CXCL8 mRNA abundance in poly(I:C)-stimulated cells by cleaving PAR1 at Arg41 and most likely by nonproteolytic transactivation of PAR2 by the PAR1-tethered ligand.

**Thrombin amplifies poly(I:C)-induced endothelial TF procoagulant function**

Immunohistological detection with anti-TF antibodies in permeabilized, poly(I:C)-treated EA.hy926 cells revealed robust augmentation of TF antigen levels by Par1 and Par2 agonist peptides (Figure 5A) that was corroborated by western blot analysis of whole-cell lysates (Figure 5B), procoagulant activity in whole-cell extracts (Figure 5C), and measurement of cell surface–associated TF activity (Figure 5D). Akin to data obtained with agonist peptides, thrombin-induced TF antigen correlated with functional TF activity in whole-cell lysates (Figure 5E), with immunostaining of cell surface–associated TF in nonpermeabilized cells (Figure 5F), and with cell surface–associated TF activity, as measured by a 2-stage factor Xa generation assay (Figure 5G). As for TF mRNA, augmentation of whole-cell TF antigen (Figure 5H) and cell surface TF activity (Figure 5I) were sensitive to pharmacologic inhibition of both Par1 and Par2. Likewise, antibodies blocking cleavage of Par1 (ATAP2/WEDE15), but not Par2 (SAM-11), suppressed cell surface TF activity by thrombin/poly(I:C) costimulation (Figure 5I). The amplification of functional TF activity in costimulated cells therefore appeared to be regulated predominantly at the level of TF gene transcription and/or mRNA stability.

**Endothelial-leukocyte adhesion in costimulated cells requires PAR1 and PAR2**

Replicating earlier findings,^{57,58} independent verification of the gene expression data by quantitative RT-PCR confirmed that thrombin and poly(I:C) each increased VCAM1 and E-selectin mRNA.
abundance and exerted a synergistic effect when given together (Figure 6A). Poly(I:C) and thrombin individually induced VCAM1 surface expression in 13% to 17% of cells (Figure 6B). Thrombin elicited coexpression of VCAM1 and E-selectin in ~5.7% of cells after 4 hours of stimulation. Costimulation with poly(I:C) and thrombin elicited coexpression of VCAM1 and E-selectin on ~20% of all cells, reflecting a ~13-fold increase compared with cells stimulated with poly(I:C) alone (Figure 6B). Adhesion of THP-1 cells to HUVEC monolayers was significantly increased by poly(I:C) (~8-fold) and further enhanced by costimulation with thrombin (~15-fold) relative to untreated cells (Figure 6C-D). Pharmacologic inhibition of PAR1 or PAR2 with vorapaxar and GB83, respectively, suppressed THP-1 adhesion similar to the effect of VCAM1- or E-selectin–blocking antibodies (Figure 6C-D).

Discussion
In the current work, we investigated how 2 signals associated with viral infections (ie, the viral RNA analogue poly(I:C)) and enhanced generation of signaling-competent blood coagulation proteases interact to alter the function of vascular ECs. Interrogation of the HUVEC transcriptome by RNA profiling showed that costimulation with thrombin and poly(I:C) induced a state of inflammatory endothelial activation distinct from that elicited by either signal alone. This response reflected in part the cooperative effects of the individual agonists (34 down, 112 up; Figure 1; Venn diagram, E-G), but also included a large number of transcripts that were significantly regulated only in costimulated cells (120 down; 127 up; Venn diagram C). Pathway analysis of gene expression data indicated that the response of genes selectively upregulated in costimulated cells predominantly reflected transcriptional activation via NF-κB complexes, whereas the subset of transcripts selectively downregulated by co stimulation may have a stronger effect on the maintenance of vascular integrity.

Although the inflammatory effect of thrombin signaling in ECs is well documented,24,59-62 only a small fraction of transcripts (17 of 292; Figure 1, Venn section F vs sum of sections A,B,D,E,F,G) were upregulated individually by both thrombin or poly(I:C) under our experimental conditions. Yet, genes within this group exhibited overall the most robust, cooperative response to costimulation (Table 1) and included endothelial adhesion receptors and cytokines central to the regulation of leukocyte accumulation at sites of infection (E-selectin/SELE, VCAM1, CXCL8, IL-6, CXCL2, and CCL2). Similarly, whereas poly(I:C) alone, compared with thrombin, had only a modest effect on TF mRNA, it conveyed a very marked synergistic effect on TF mRNA abundance in costimulated cells. A key observation from the analyses was therefore that the coincident activation of TLR3 by poly(I:C) and of PAR1 and 2 by thrombin selectively elicited a synergistic activation of the 2 critical biological mechanisms promoting endothelial thromboinflammatory functions: the initiation of blood coagulation and the control of leukocyte trafficking.

The correlations between mRNA abundance, protein antigen levels, and surface expression, as well as functional activity for TF and the adhesion receptors VCAM1 and E-selectin, indicate that the proinflammatory and procoagulant effects of poly(I:C)/thrombin costimulation are regulated predominantly at the level of gene transcription and/or mRNA stability. However, thrombin or poly(I:C) each enhanced the abundance of VCAM1 and E-selectin mRNA, but only VCAM1 antigen expression was induced on the cell surface by either ligand alone. In contrast, costimulation with poly(I:C) and thrombin led to significant coexpression of both receptors, which is likely to be necessary for efficient leukocyte tethering.63

To gain a mechanistic understanding of the relative contributions of direct thrombin signaling and secondary TF-dependent signaling, we showed that the effect of thrombin could be replicated only by synthetic tethered ligands derived from PAR1 and PAR2, but not from PAR3 or PAR4. Of note, PAR2-selective agonists consistently yielded a more robust response than PAR1- or PAR1/2-elective agonists, indicating the dominant role of PAR2 activation. We investigated 3 established paradigms of PAR2 activation: (1) activation of PAR1/2 by FXa, the TF-VIIa complex, or the TF-VIIa-Xa complex;22,23 (2) direct activation of PAR2 by thrombin or the thrombin-Thbd complex;34,64; and (3) transactivation of PAR2 by thrombin-cleaved PAR1.53 Although FXa has been reported to induce TF activity in HUVECs,65 we ruled out a significant role of a TF-dependent mechanism, direct signaling by factors Xa and VIIa generated as a consequence of TF-mediated coagulation initiation, and direct activation of PAR2 by thrombin-Thbd complexes. Instead, our observations indicate that thrombin is the principal physiologic protease triggering thromboinflammatory feedback amplification via proteolytic cleavage of PAR1, and potentially, transactivation of PAR2 by the PAR1-tethered ligand. Given that PAR2 inhibition completely blocked the effects of a PAR1 agonist, we suspect that the relevant thrombin target is indeed a physical PAR1/2 heterodimer, in which PAR1 inhibition with vorapaxar is still compatible with the agonist-induced transition of PAR2 into a signaling-compotent conformation. Independent earlier studies showed that induction of decay-accelerating factor by thrombin likewise proceeds through activation of PAR1/2 heterodimers.66 Notably, in this study PAR1 activation was coupled to PKC-α, whereas PAR2 signaling required PKC-ε. Our own experimental approaches were not informative as to whether the cooperativity between PAR1 and PAR2 reflects intracellular integration of distinct signaling cascades initiated via each receptor or is caused by a specific signaling platform composed of physical PAR1/2 heterodimers. A further limitation in the interpretation of data from cross-inhibition experiments with PAR1/2 agonists and GB83 is the known cross-reactivity of the PAR1 agonist SFLRN-NH2 with PAR2 and the albeit limited potential for PAR1 inhibition by the PAR2-selective inhibitor GB83.67 Our findings also suggest that selective, physiologically relevant agonists of PAR2 may elicit, or propagate a similar modulation of the poly(I:C) response, as shown herein for thrombin. For example, in the presence of VII and IX, the initial poly(I:C)-induced increase in TF expression could lead to direct PAR2 activation by the TF-VIIa and/or TF-VIIa-Xa complexes, or indirectly via transactiva- tion of promatriptase by the ternary TF-VIIa-Xa complex and ensuing PAR2 activation by matriptase.68

A seminal report on the importance of PAR1/2 heterodimers in mouse models of endotoxemia and sterile inflammation described the disease stage–dependent opposing effects of PAR1 activation over the course of sepsis, with PAR1 activation being detrimental in the early stages, but protective in the later stages.69 In that study, results of in vitro experiments on human ECs suggested that the switch from detrimental to protective PAR1 effects requires PAR2 and involves the lipopolysaccharide (LPS)-induced recruitment of intracellular PAR2 into cell surface–associated PAR1/2 hetero- dimers. The study did not ascertain that the in vivo protective effects of PAR1/2 agonism were indeed dependent on endothelial PAR2 expression and used different inflammatory stimuli (LPS) and...
readouts of endothelial function (barrier integrity) than our current work. Nevertheless, these observations raise new questions of to what extent the apparent role of PAR1/2 heterodimers may depend on the species investigated, the specific nature of the inflammatory/infectious challenge (LPS-TLR4 vs poly[I:C]-TLR3), the effects on non-EC types, and the specific biased or unbiased mechanisms of action of PAR1/2 agonists.

The concept that inflammatory mediators alter the response capacity of ECs to thrombin has been demonstrated earlier. Preincubation of HUVECs with TNFα and LPS significantly inhibited, rather than amplified, thrombin-mediated induction of VCAM1, ICAM, TF, and E-selectin. This result strongly suggests that the endothelial thrombin response may vary substantially, depending on the specific mediator mix present in the blood of patients with a given disease. In addition, different types of ECs likely exhibit distinct cytokine responses in vitro as well as organ-specific LPS responses in vivo.

In summary, our findings expand the existing evidence that inflammatory cytokines and danger signals other than poly(I:C), as shown here, synergize with thrombin and other PAR agonists, such as matrix metalloproteinase 1 and peptidocins, to modify and amplify thromboinflammatory functions of the endothelium. The amplification of TF procoagulant activity by thrombin in poly(I:C)-treated cells implies that thrombin, whether initially generated as a consequence of TF expression on inflammatory immune cells, such as macrophages, or on infected endothelium itself, may sustain and amplify its own formation by further enhancing TF expression on endothelium. In essence, this mechanism therefore constitutes a feedback amplification of thromboinflammatory functions of virus-exposed endothelium. Mechanistically, the current work showed that this thrombin-mediated feedback requires PAR1/2 heterodimers and may be inhibited by PAR2 antagonists, providing an incentive for further development and evaluation of monovalent or heterovalent antagonists of PAR1-PAR2 heterodimers as a potential therapeutic to reduce endothelial dysfunction.

Acknowledgments

The authors thank Wolfram Ruf and Skip Brass for providing reagents and the BRI Core facility staff for their support and expertise.

This work was supported by National Institutes of Health, National Heart, Lung, and Blood Institute grants R01HL142799 (S.A.), R01HL119523 (N.M.), R01HL117132 (H.W.), and R15HL127636 (C.D.) and the Office of the Director R25OD014807 (C.F.); and by the Richard Gallagher Fellowship Award from the Versiti Blood Research Foundation (S.S.).

Authorship

Contribution: S.S. performed the experiments, analyzed the data, and contributed to writing the manuscript; Y.O., I.H., and F.B. performed the experiments; R.B., S.S., and H.W. analyzed the RNA-sequencing data; N.M., S.A., and C.F. provided expert technical advice and contributed to the study; M.Z. and I.H. conducted CRISPR/Cas9 genome editing and flow cytometry; and S.S. and H.W. designed the experiments, analyzed the data, and wrote the manuscript.

Conflict-of-interest disclosure: C.D. is the founder of a company (Function Therapeutics LLC) that is developing anti-inflammatory PAR ligands (not included in this manuscript). The remaining authors declare no competing financial interests.

The current affiliation for S.S. is Pulmonary Center, Boston University School of Medicine, Boston, MA.

ORCID profiles: C.D., 0000-0002-4092-5636; S.A., 0000-0001-5523-825X.

Correspondence: Hartmut Weiler, Blood Research Institute, Versiti, 8727 Watertown Plank Rd, Milwaukee, WI 53226; e-mail: hweiler@versiti.org.

References

1. Subramaniam S, Scharrer I. Procoagulant activity during viral infections. Front Biosci. 2018;23(3):1060-1081.
2. Antoniak S. The coagulation system in host defense. Res Pract Thromb Haemost. 2018;2(3):549-557.
3. Bierhaus A, Illmer T, Kasper M, et al. Advanced glycation end product (AGE)-mediated induction of tissue factor in cultured endothelial cells is dependent on RAGE. Circulation. 1997;96(7):2262-2271.
4. Yang Y, Tang H. Aberrant coagulation causes a hyper-inflammatory response in severe influenza pneumonia. Cell Mol Immunol. 2016;13(4):432-442.
5. Giannis D, Ziogas IA, Gianni P. Coagulation disorders in coronavirus infected patients: COVID-19, SARS-CoV-1, MERS-CoV and lessons from the past. J Clin Virol. 2020;127:104362.
6. Mackman N, Antoniak S, Wolberg AS, Kasthuri R, Key NS. Coagulation Abnormalities and Thrombosis in Patients Infected With SARS-CoV-2 and Other Pandemic Viruses. Arterioscler Thromb Vasc Biol. 2020;40(9):2033-2044.
7. Marongiu F, Grandone E, Barcellona D. Pulmonary thrombosis in 2019-nCoV pneumonia? J Thromb Haemost. 2020;18(6):1511-1513.
8. Bilkeli B, Madhavan MV, Jimenez D, et al; Global COVID-19 Thrombosis Collaborative Group, Endorsed by the ISTH, NATF, ESVM, and the IUA, Supported by the ESC Working Group on Pulmonary Circulation and Right Ventricular Function. COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review. J Am Coll Cardiol. 2020;75(23):2950-2973.
9. McFadyen JD, Stevens H, Peter K. The Emerging Threat of (Micro)Thrombosis in COVID-19 and Its Therapeutic Implications. Circ Res. 2020;127(4):571-587.
10. Cui S, Chen S, Li X, Liu S, Wang F. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J Thromb Haemost. 2020;18(6):1421-1424.
11. Klok FA, Kruip MJHA, van der Meer NJM, et al. Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: An updated analysis. *Thromb Res.* 2020;191:148-150.

12. Helms J, Tacquard C, Severac F, et al; CRICS TRIGGERSEP Group (Clinical Research in Intensive Care and Sepsis Trial Group for Global Evaluation and Research in Sepsis). High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. *Intensive Care Med.* 2020;46(6):1089-1098.

13. Oxley TJ, Mocco J, Majidi S, et al. Large-Vessel Stroke as a Presenting Feature of Covid-19 in the Young. *N Engl J Med.* 2020;382(20):e60.

14. Bellotta R, Luzzani L, Natalini G, et al. Acute limb ischemia in patients with COVID-19 pneumonia. *J Vasc Surg.* 2020;72(6):1864-1872.

15. Wenzler E, Engineer MH, Yaqoob M, Benken ST. Safety and Efficacy of Apixaban For Therapeutic Anticoagulation in Critically Ill ICU Patients with Severe COVID-19 Respiratory Disease. *Th Open.* 2020;4(4):e376-e382.

16. Daugherty MM, Morgan A, Frost E, et al. COVID-19 associated coagulopathy: Thrombosis, hemorrhage and mortality rates with an escalated-dose thromboprophylaxis strategy. *Thromb Res.* 2020;196:483-485.

17. Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. *J Thromb Haemost.* 2020;18(5):1094-1099.

18. Varga Z, Flammer AJ, Steiger P, et al. Endothelial cell infection and endothelitis in COVID-19. *Lancet.* 2020;395(10234):1417-1418.

19. Teuwen LA, Geldhof V, Pasut A, Carmeliet P. COVID-19: the vasculature unleashed [published correction appears in *Nat Rev Immunol.* 2020;20(7):448]. *Nat Rev Immunol.* 2020;20(7):389-391.

20. Gustafsson D, Raju S, Wu R, et al. Overcoming Barriers: The Endothelium As a Linchpin of Coronavirus Disease 2019 Pathogenesis? *Arterioscler Thromb Vasc Biol.* 2020;40(8):1819-1829.

21. Gupta A, Madhavan MV, Selgal K, et al. Extrapulmonary manifestations of COVID-19. *Nat Med.* 2020;26(7):1017-1032.

22. Posma JJ, Grover SP, Hisada Y, et al. Roles of Coagulation Proteases and PARs (Protease-Activated Receptors) in Mouse Models of Inflammation, Obesity, and Thrombosis. *Arterioscler Thromb Vasc Biol.* 2019;39(1):13-24.

23. Samad F, Ruf W. Inflammation, obesity, and thrombosis. *Blood.* 2013;122(20):3415-3422.

24. Minami T, Sugiyama A, Wu SQ, Abid R, Kodama T, Aird WC. Thrombin and phenotypic modulation of the endothelium. *Arterioscler Thromb Vasc Biol.* 2004;24(1):41-53.

25. Chandrasekharan UM, Yang L, Walters A, Howe P, DiCorleto PE. Role of CL-100, a dual specificity phosphatase, in thrombin-induced endothelial cell activation. *J Biol Chem.* 2004;279(45):48678-48685.

26. van den Biggelaar M, Hernández-Fernaud JR, van den Eshof BL, et al. Quantitative phosphoproteomics unveils temporal dynamics of thrombin signaling in human endothelial cells. *Blood.* 2014;123(12):e22-e36.

27. Bartha K, Brisson C, Archipoff G, et al. Thrombin regulates tissue factor and thrombomodulin mRNA levels and activities in human saphenous vein endothelial cells by distinct mechanisms. *J Biol Chem.* 1993;268(1):421-429.

28. Hamming I, Timens W, Bulthuis ML, Lely AT, Navis G, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS-CoV-2. *EMBO Rep.* 2020;21(10):e103124.

29. Shibamiya A, Hersemeyer K, Schmidt W, et al. A key role for Toll-like receptor-3 in disrupting the hemostasis balance on endothelial cells. *Blood.* 2009;113(3):714-722.

30. Chen W, Lan Y, Yuan X, et al. Detectable 2019-nCoV viral RNA in blood is a strong indicator for the further clinical severity. *Emerg Microbes Infect.* 2020;9(1):469-473.

31. Monteil V, Kwon H, Prado P, et al. Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2. *Cell.* 2020;181(4):905-913.e7.

32. Koo BS, Oh H, Kim G, et al. Transient Lymphopenia and Interstitial Pneumonia With Endotheliitis in SARS-CoV-2-Infected Macaques. *J Infect Dis.* 2020;222(10):1596-1600.

33. Shimabukuro H, Horsemeyer K, Schmidt Wölfl T, et al. A key role for Toll-like receptor-3 in disrupting the hemostasis balance on endothelial cells. *Blood.* 2009;113(4):714-722.

34. Carson SD, Ross SE, Bach R, Guha A. An inhibitory monoclonal antibody against human tissue factor. *Blood.* 1987;70(2):490-493.

35. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. *Methods.* 2001;25(4):402-408.

36. Orjuela S, Huang R, Hembach KM, Robinson MD, Soneson C. ARMOR: An Automated Reproducible MOdular Workflow for Preprocessing and Differential Analysis of RNA-seq Data. *G3 (Bethesda).* 2019;9(7):2089-2096.

37. Davis CL, Bussolino F. The role of endothelial cells in the pathogenesis of SARS-CoV-2 infection. *Arterioscler Thromb Vasc Biol.* 2020;40(8):1819-1829.

38. Lundberg AM, Drumier SK, Monaco C, et al. Key differences in TLR3/poly I:C signaling and cytokine induction by human primary cells: a phenomenon absent from murine cell systems. *Blood.* 2007;110(8):3245-3252.

39. Huang LY, Stuart C, Takeda K, D’Agnillo F, Golding B. Poly(I:C) Induces Human Lung Endothelial Barrier Dysfunction by Disrupting Tight Junction Expression of Claudin-5. *PLoS One.* 2016;11(8):e0160875.

40. McLaughlin JN, Mazzeni MR, Cleator JH, et al. Thrombin modulates the expression of a set of genes including thrombospordin-1 in human microvascular endothelial cells. *J Biol Chem.* 2005;280(23):22172-22180.
41. Ellinghaus P, Perzborn E, Hauenschild P, et al. Expression of pro-inflammatory genes in human endothelial cells: Comparison of rivaroxaban and dabigatran. *Thromb Res.* 2016;142:44-51.

42. Wilson C, Lee MD, McCarron JG. Acetylcholine released by endothelial cells facilitates flow-mediated dilatation. *J Physiol.* 2016;594(24):7287-7307.

43. Hogan NT, Whalen MB, Stolze LK, et al. Transcriptional networks specifying homeostatic and inflammatory programs of gene expression in human aortic endothelial cells. *eLife.* 2017;6:e22536.

44. Krissin S, Stratman AN, Melick CH, et al. Growth Differentiation Factor 6 Promotes Vascular Stability by Restraining Vascular Endothelial Growth Factor Signaling. *Arterioscler Thromb Vasc Biol.* 2018;38(2):353-362.

45. Xu J, Sheng Z, Li F, et al. NEDD4 protects vascular endothelial cells against Angiotensin II-induced cell death via enhancement of XPO1-mediated nuclear export. *Exp Cell Res.* 2019;383(1):11505.

46. Sabater-Lleal M, Huffman JE, de Vries PS, et al; INVENT Consortium; MEGASTROKE Consortium of the International Stroke Genetics Consortium (ISGC). Genome-Wide Association Transethnic Meta-Analyses Identifies Novel Associations Regulating Coagulation Factor VIII and von Willebrand Factor Plasma Levels. *Circulation.* 2019;139(5):620-635.

47. Seo SW, Koeppen M, Bonney S, et al. Differential Tissue-Specific Function of Adora2b in Cardioprotection. *J Immunol.* 2015;195(4):1732-1743.

48. Gruber F, Hufnagl P, Hofer-Warbinek R, et al. Direct binding of Nur77/NAK-1 to the plasminogen activator inhibitor 1 (PAI-1) promoter regulates TNF alpha-induced PAI-1 expression. *Blood.* 2003;101(8):3042-3048.

49. Zhao Y, Howatt DA, Gizard F, et al. Deficiency of the NR4A orphan nuclear receptor NOR1 decreases monocyte adhesion and atherosclerosis. *Circ Res.* 2010;107(4):501-511.

50. Arkenbout EK, van Bragt M, Eldering E, et al. TR3 orphan receptor is expressed in vascular endothelial cells and mediates cell cycle arrest. *Arterioscler Thromb Vasc Biol.* 2003;23(9):1535-1540.

51. Zhu N, Zhang GX, Yi B, et al. Nur77 limits endothelial barrier disruption to LPS in the mouse lung. *Am J Physiol Lung Cell Mol Physiol.* 2019;317(5):L815-L824.

52. You B, Jiang YY, Chen S, Yan G, Sun J. The orphan nuclear receptor Nur77 suppresses endothelial cell activation through induction of IkappaBalpha expression. *Circ Res.* 2009;104(6):742-749.

53. Nieman MT. Protease-activated receptors in hemostasis. *Blood.* 2016;128(2):169-177.

54. Heuberger DM, Franchini AG, Madon J, Schuepbach RA. Thrombin cleaves and activates the protease-activated receptor 2 dependent on thromboxane A2. *Thromb Res.* 2019;177:91-101.

55. Schuepbach RA, Madon J, Ender M, Galli P, Riewald M. Protease-activated receptor-1 cleaved at R46 mediates cytoprotective effects. *J Thromb Haemost.* 2012;10(8):1675-1684.

56. Shi X, Gangadharan B, Brass LF, Rul F, Mueller BM. Protease-activated receptors (PAR1 and PAR2) contribute to tumor cell motility and metastasis. *Mol Cancer Res.* 2004;2(7):395-402.

57. Kaplanski G, Marin V, Fabrigoule M, et al. Thrombin-activated human endothelial cells support monocyte adhesion in vitro following expression of intercellular adhesion molecule-1 (ICAM-1; CD54) and vascular cell adhesion molecule-1 (VCAM-1; CD106). *Blood.* 1998;92(4):1259-1267.

58. Hassanian SM, Dinarvand P, Rezaie AR. Adenosine regulates the proinflammatory signaling function of thrombin in endothelial cells. *J Cell Physiol.* 2014;229(9):1292-1300.

59. Mhatre MV, Potter JA, Lockwood CJ, Krikun G, Abrahams VM. Thrombin Augments LPS-Induced Human Endothelial Cell Inflammation by Activation of the NR4A orphan nuclear receptor NOR1 decreases monocyte adhesion and atherosclerosis. *Exp Cell Res.* 2017;6:e22536.

60. Kalz J, ten Cate H, Spronk HM. Thrombin generation and atherosclerosis. *J Thromb Thrombolysis.* 2010;37(1):45-55.

61. Alabanza LM, Bynoe MS. Thrombin induces an inflammatory phenotype in a human brain endothelial cell line. *J Neuroimmunol.* 2012;245(1-2):48-55.

62. Zhang LO, Cherenova D, Gibson M, et al. RNA-seq reveals novel transcriptome of genes and their isoforms in human pulmonary microvascular endothelial cells treated with thrombin. *PLoS One.* 2012;7(2):e31229.

63. Ley K, Laudanna C, Cybulsky MI, Nourshargh S. Getting to the site of inflammation: the leukocyte adhesion cascade updated. *Nat Rev Immunol.* 2007;7(7):678-689.

64. Mihara K, Ramachandran R, Saifeddine M, et al. Thrombin-Mediated Direct Activation of Proteinase-Activated Receptor-2: Another Target for Thrombin Signaling. *Mol Pharmacol.* 2016;89(5):606-614.

65. Jiang R, Wang NP, Tanaka KA, et al. Factor Xa induces tissue factor expression in endothelial cells by P44/42 MAPK and NF-kB-dependent pathways. *J Surg Res.* 2011;169(2):319-327.

66. Ledington EA, Steinberg R, Kinderlerer AR, et al. A role for proteinase-activated receptor 2 and PKC-epsilon in thrombin-mediated induction of decay-accelerating factor on human endothelial cells. *Am J Physiol Cell Physiol.* 2005;289(6):C1437-C1447.

67. Barry GD, Suen JY, Le GT, Cotterell A, Reid RC, Fairlie DP. Novel agonists and antagonists for human protease activated receptor 2. *J Med Chem.* 2010;53(20):7428-7440.

68. Le Gall SM, Szabo R, Lee M, et al. Matriptase activation connects tissue factor-dependent coagulation initiation to epithelial proteinase and signaling. *Blood.* 2016;127(25):3260-3269.
69. Kaneider NC, Leger AJ, Agarwal A, et al. ‘Role reversal’ for the receptor PAR1 in sepsis-induced vascular damage. *Nat Immunol.* 2007;8(12):1303-1312.

70. Wada Y, Otu H, Wu S, et al. Preconditioning of primary human endothelial cells with inflammatory mediators alters the “set point” of the cell. *FASEB J.* 2005;19(13):1914-1916.

71. Franscini N, Bachli EB, Blau N, Loikauf MS, Schoedon A, Schoedon G. Gene expression profiling of inflamed human endothelial cells and influence of activated protein C. *Circulation.* 2004;110(18):2903-2909.

72. Sana TR, Janatpour MJ, Sathe M, McEvoy LM, McClanahan TK. Microarray analysis of primary endothelial cells challenged with different inflammatory and immune cytokines. *Cytokine.* 2005;29(6):256-269.

73. Cleuren ACA, van der Ent MA, Jiang H, et al. The in vivo endothelial cell translatome is highly heterogeneous across vascular beds. *Proc Natl Acad Sci USA.* 2019;116(47):23618-23624.

74. Rana R, Huang T, Koukos G, et al. Noncanonical Matrix Metalloprotease 1-Protease-Activated Receptor 1 Signaling Drives Progression of Atherosclerosis. *Arterioscler Thromb Vasc Biol.* 2018;38(6):1368-1380.

75. Liu Y, Pelekanakis K, Woolkalis MJ. Thrombin and tumor necrosis factor alpha synergistically stimulate tissue factor expression in human endothelial cells: regulation through c-Fos and c-Jun. *J Biol Chem.* 2004;279(34):36142-36147.

76. Riewald M, Ruf W. Protease-activated receptor-1 signaling by activated protein C in cytokine-perturbed endothelial cells is distinct from thrombin signaling. *J Biol Chem.* 2005;280(20):19808-19814.

77. Antoniak S, Tatsumi K, Schmedes CM, et al. PAR1 regulation of CXLC1 expression and neutrophil recruitment to the lung in mice infected with influenza A virus. *J Thromb Haemost.* 2021;19(4):1103-1111.

78. Majewski MW, Gandhi DM, Rosas R Jr, Kodali R, Arnold LA, Dockendorff C. Design and Evaluation of Heterobivalent PAR1-PAR2 Ligands as Antagonists of Calcium Mobilization. *ACS Med Chem Lett.* 2018;10(1):121-126.